** Hoth Therapeutics' shares rise 15% to $1.17 in early trade
** Co announces positive preclinical study results for their HT-ALZ investigational Alzheimer's drug
** The study data shows improved cognitive function among the Alzheimer's model mice treated with HT-ALZ
** HOTH notes early observations point to a potential link between reduced reactive astrocytic activity in parts of the brain and improved cognitive function
** Up to Monday's close, stock had fallen ~30% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments